Extracto de Polypodium leucotomos en dermatitis atópica: Ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo / Polypodium leucotomos Extract in Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Background: Several studies have reported an association between tumor necrosis factor Introducción: Para el control de la lesión inflamatoria de la dermatitis atópica, y secundariamente del prurito, se utilizan corticosteroides tópicos, pero su empleo está limitado por las reacciones adversas. Objetivos: El objetivo primario del estudio fue evaluar si el tratamiento diario con extracto de Polypodium leucotomos permitiría reducir el uso de corticosteroides tópicos en niños y adolescentes con dermatitis atópica. Secundariamente se valoró el consumo de antihistamínicos orales, así como la evolución de la enfermedad. Pacientes y métodos: Se ha realizado un ensayo clínico en fase IV , multicéntrico, aleatorizado y doble ciego de extracto de Polypodium leucotomos, controlado con placebo, en 105 pacientes de 2 a 17 años de edad, con dermatitis atópica de intensidad moderada e indicación de corticosteroides tópicos. Los pacientes recibieron durante 6 meses extracto de Polypodium leucotomos o placebo por vía oral añadidos al protocolo terapéutico habitual, y se calculó el porcentaje de días en que se utilizaban corticosteroides tópicos u otros tratamientos para la dermatitis atópica. Resultados: El extracto de Polypodium leucotomos redujo de modo no significativo el uso de corticosteroides tópicos (11±12% de días), comparado con placebo (12±11%). El porcentaje de días en los que los pacientes requirieron antihistamínicos orales fue significativamente menor con extracto de Polypodium leucotomos (mediana de 4,5% días) que con placebo (13,6%) (p=0,038). También se redujo el porcentaje de pacientes que tomaron antihistamínicos orales. Conclusiones: El tratamiento prolongado con extracto de Polypodium leucotomos aporta beneficios relevantes para los pacientes en edad pediátrica con dermatitis atópica que precisan tratamiento farmacológico para controlar la lesión inflamatoria y reducir el prurito (AU)

Introduction: Topical corticosteroids are used to treat inflammation and relieve itching in atopic dermatitis, but their use is limited by adverse reactions. Objectives: The main aim of this study was to investigate whether daily treatment with Polypodium leucotomos extract would reduce the use of topical corticosteroids in children and adolescents with atopic dermatitis. We also analyzed oral antihistamine use and changes in disease severity. Patients and methods: We performed a phase IV randomized, double-blind, placebo-controlled, multicenter trial involving 105 patients aged between 2 and 17 years who were receiving topical corticosteroids to treat moderate atopic dermatitis. The patients were randomized to receive, in addition to their standard treatment, Polypodium leucotomos extract or placebo (both in capsule form) for 6 months. The percentage of days on which topical corticosteroids and other atopic dermatitis treatments were used was calculated. Results: Use of Polypodium leucotomos extract did not significantly reduce the mean (SD) percentage of days on which topical corticosteroids were used (11% [12%] vs 12% [11%] for placebo). A significant reduction was, however, observed for oral histamine use (median percentage of days, 4.5% in the Polypodium leucotomos group and 13.6% in the placebo group [P= 0.038]). The percentage of patients who used oral antihistamines was also lower in the Polypodium leucotomos group. Conclusion: Long-term treatment with Polypodium leucotomos extract has benefits for children and adolescents with atopic dermatitis who require pharmacologic treatment to reduce inflammation and relieve itching (AU)

Polypodium leucotomos extract in atopic dermatitis: a randomized, double-blind, placebo-controlled, multicenter trial.

INTRODUCTION: Topical corticosteroids are used to treat inflammation and relieve itching in atopic dermatitis, but their use is limited by adverse reactions. OBJECTIVES: The main aim of this study was to investigate whether daily treatment with Polypodium leucotomos extract would reduce the use of topical corticosteroids in children and adolescents with atopic dermatitis. We also analyzed oral antihistamine use and changes in disease severity. PATIENTS AND METHODS: We performed a phase IV randomized, double-blind, placebo-controlled, multicenter trial involving 105 patients aged between 2 and 17 years who were receiving topical corticosteroids to treat moderate atopic dermatitis. The patients were randomized to receive, in addition to their standard treatment, Polypodium leucotomos extract or placebo (both in capsule form) for 6 months. The percentage of days on which topical corticosteroids and other atopic dermatitis treatments were used was calculated. RESULTS: Use of Polypodium leucotomos extract did not significantly reduce the mean (SD) percentage of days on which topical corticosteroids were used (11% [12%] vs 12% [11%] for placebo). A significant reduction was, however, observed for oral histamine use (median percentage of days, 4.5% in the Polypodium leucotomos group and 13.6% in the placebo group [P= .038]). The percentage of patients who used oral antihistamines was also lower in the Polypodium leucotomos group. CONCLUSION: Long-term treatment with Polypodium leucotomos extract has benefits for children and adolescents with atopic dermatitis who require pharmacologic treatment to reduce inflammation and relieve itching.

Lepra lepromatosa de evolucion mortal

Se presenta el caso de un enfermos LL de 68 años de edad, intensamente positivo dianosticado hace 2 meses, que ingresa con un cuadro con lesiones úlcero-necróticas que afetan un 50% del tegumento, mal estado general y anemia. No obstante el tratamiento específico, corticoterapia y hemoterapia fallece a los 20 días.

[Gunther's congenital erythropoietic porphyria in an 8-month old girl (author's transl)]. / Porphyrie érythropoïétique congénitale de Gunther chez une fillette de huit mois

A typical case of congenital erythropoietic porphyria in a 8 month old girl is reported (photosensitive blistering syndrome, hypertrichosis; erythrodontia; fluorescence of urine, teeth, erythrocytes and myeloblasts; splenomegaly; anaemia). Porphyrins, isomers I, were present in urine and blood. In faeces a porphyrin-X-like substance migrating as PX was detected; this porphyrin was finally identified as CP I unusually difficult to extract because of the presence of a banding and fluorescence quenching agent probably of exogenous origin. The usual methods are not always able to extract and to identify the faecal porphyrins.